Login to Your Account



Financings Roundup


Wednesday, June 1, 2011
Excelimmune Inc., of Woburn, Mass., closed a Series B financing worth $10.5 million to advance its antibiotic candidate Staphguard. The drug is a human recombinant polyclonal antibody designed to target methicillin-resistant Staphylococcus aureus. The funds will also be used to improve the company's discovery platform and finish proof-of-principle work on its manufacturing system.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription